Factor XII inhibitors for the treatment of neurological inflammatory disorders
AssigneesCSL Behring GmbH, CSL Limited, Julius-Maximilians-Universitaet Wuerzburg, Westfaelische Wilhelms-Universitaet Muenster
InventorsSven Meuth, Kerstin Goebel, Christoph Kleinschnitz, Brent McKenzie, Marc Nolte
Life of this patent
Estimating the term…
Abstract
This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided.
Claims14
A method for treatment and/or amelioration of multiple sclerosis comprising administering to a subject in need thereof a therapeutically effective amount of a direct inhibitor of Factor XII (FXII), wherein the direct inhibitor of FXII contacts FXII to inhibit the activity and/or activation of FXII in the subject.
Dependencies are inferred from the claim text.